Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01831453
Other study ID # Dr. Amr Elkhouli 1962
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received April 5, 2013
Last updated April 10, 2013
Start date April 2012
Est. completion date May 2013

Study information

Verified date April 2013
Source October 6 University
Contact n/a
Is FDA regulated No
Health authority Egypt: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The study aims at evaluating the effect of omega-3 on patients suffering recurrent oral aphthous ulcers


Description:

In this study, we tested the hypothesis that the administration of omega 3 improve the quality of life in patients suffering recurrent oral ulceration and improve associated symptoms of pain in addition to reduction of ulcers episode.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 50
Est. completion date May 2013
Est. primary completion date April 2013
Accepts healthy volunteers No
Gender Both
Age group 13 Years to 70 Years
Eligibility Inclusion Criteria:

1. Male and female patients older than 13 years of age

2. Presenting with 1 to 3 aphthous ulcers (less than 48 hours' duration) with a size no greater than 5mm in diameter.

3. History of recurrent minor aphthous ulcer for at least one year with a frequency of at least one outbreak every one month.

4. Normal sense of pain, without anesthesia or paresthesia.

5. Willingness to participate and sign the informed consent.

Exclusion Criteria:

- 1- Concurrent clinical conditions that could pose a health risk to the subjects including serious heart, liver, or kidney dysfunctions.

2- Pregnancy and lactation. 3- Ulcers as a manifestation of systemic disorders such as Ulcerative Colitis, Crohn's disease, Behçet's syndrome or serious anemia.

4- Treatment with systemic steroids, immunomodulatory agents, antibiotics, non-steroidal anti-inflammatory drugs (except occasional use for headaches) one month prior to the study entry.

5- Treatment of the current ulcer with any topical or systemic medication. 6- Attendance of any other clinical trials prior to 3 months of study entry.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
omega-3
polyunsaturated fatty acids(PUFAs) 1 gram three times per day for 6 months
placebo
soft gelatinous capsules filled with isopropylmyristate oil

Locations

Country Name City State
Egypt October 6 university Cairo Governarate of 6 of October

Sponsors (2)

Lead Sponsor Collaborator
October 6 University Tanta University

Country where clinical trial is conducted

Egypt, 

References & Publications (1)

Hjorth E, Zhu M, Toro VC, Vedin I, Palmblad J, Cederholm T, Freund-Levi Y, Faxen-Irving G, Wahlund LO, Basun H, Eriksdotter M, Schultzberg M. Omega-3 fatty acids enhance phagocytosis of Alzheimer's disease-related amyloid-ß42 by human microglia and decrease inflammatory markers. J Alzheimers Dis. 2013;35(4):697-713. doi: 10.3233/JAD-130131. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary quality of life Measurement of oral health related quality of life (OHR-QoL),this parameter was carried out at baseline, and at 6 months of the study using the Arabic version of oral health impact profile-14 (OHIP-14) questionnaire. six months No
Secondary Pain associated with the ulcers The measurements for treatment effectiveness included evaluation of pain associated with the ulcer(s) by means of visual analogue scales (VAS). Six months No
Secondary Duration of ulcers episode The time needed for the ulcer to heal Six months No
Secondary The monthly number of ulcer outbreaks The number of ulcers appears monthly in the mouth Monthly for six months No